Biotech Investors & VC Firms in Switzerland

92 firms in this list, with a median first check of $540K. 23 of them lead rounds. Generated from verified public data and updated continuously.

Fund	FoxScore	HQ	Invests	Stage	Check	CRM
DE Delin Ventures ILCFIDJH21 people	88🔒	London	GB	Pre-Seed–Series A	$216K – $2.2M	+ Add to CRM
MA Maximon CWDTJRIS23 people	88🔒	Zug	CH	Pre-Seed–Series A	$11M	+ Add to CRM
IN Invivo Capital Partners AFLPGGBC11 people	88🔒	Barcelona	ES	Pre-Seed–Series A	$2.2M – $4.3M	+ Add to CRM
DE Debiopharm Innovation Fund MCTMTGVL13 people · Leads rounds	88🔒	Lausanne	CH	Pre-Seed–Late Stage	$1M – $5M	+ Add to CRM
GR Grazia Equity GmbH ARJKASKU8 people · Leads rounds	88🔒	Stuttgart	DE	Seed–Late Stage	$540K – $2.7M	+ Add to CRM
AM Amino Collective MGNPFTCG8 people	88🔒	Berlin	DE	Pre-Seed–Series A	$216K – $1.6M	+ Add to CRM
KI Kinled Holding PA1 person · Leads rounds	88🔒	Hong Kong	HK	Seed–Series A	—	+ Add to CRM
LB LBBW Venture Capital GmbH AVFMCLMN9 people	88🔒	Stuttgart	DE	Seed–Late Stage	$540K – $3.2M	+ Add to CRM
SU Supermoon Capital PCGJMMCZ6 people · Leads rounds	88🔒	San Francisco	US	Pre-Seed–Series A	$150K – $2.5M	+ Add to CRM
ÜB Übermorgen Ventures JHABALEW6 people · Leads rounds	88🔒	Zurich	CH	Pre-Seed–Series A	$330K – $1.1M	+ Add to CRM
AM AMR Action Fund HSMHJGBB13 people	88🔒	Boston	US	Seed–Series C	—	+ Add to CRM
AU Auriga Partners JCCLGRMC15 people	88🔒	Paris	FR	Seed–Growth	$540K – $5.4M	+ Add to CRM
PU Pureos Bioventures DEKBMMVG11 people	88🔒	Pfäffikon	CH	Seed–Series C	—	+ Add to CRM
SI Simon Capital FDJLNHNL5 people · Follows rounds	88🔒	Düsseldorf	DE	Seed–Series A	$540K – $10.8M	+ Add to CRM
IN Infinitas Capital RLSLACAL16 people	88🔒	—		Pre-Seed–Late Stage	—	+ Add to CRM
GI Gimv AJLTMMPV11 people · Leads rounds	88🔒	The Hague	BE	Growth–Late Stage	$21M – $430M	+ Add to CRM
NO Novalis Biotech JVWVKMJB9 people	88🔒	Ghent	BE	Pre-Seed–Series A	—	+ Add to CRM
EL Elysia Capital MLSBFMFB7 people	88🔒	Turin	IT	—	—	+ Add to CRM
PA PAI Partners AAAAEAEA8 people	88🔒	Paris	FR	Growth–Late Stage	$108M – $324M	+ Add to CRM
TI TiVenture SA LLPODMRG5 people	88🔒	Lugano	CH	Pre-Seed–Series B	—	+ Add to CRM
AE Aescap Life Sciences PKPDBJGH14 people	88🔒	Amsterdam	NL	Seed–Growth	—	+ Add to CRM
TI Ti-Ventures LLPODMRG5 people · Leads rounds	88🔒	Lugano	CH	Pre-Seed–Series B	—	+ Add to CRM
EU Eurazeo LGLMMTNW12 people	88🔒	Paris	FR	Series A–Late Stage	—	+ Add to CRM
PM PM Equity Partner AGACCODS9 people	88🔒	Lausanne	CH	Series A–Growth	$2M – $50M	+ Add to CRM

Delin Ventures

LondonPre-Seed–Series A$216K – $2.2M

ILCFIDJH21 people

Maximon

ZugPre-Seed–Series A$11M

CWDTJRIS23 people

Invivo Capital Partners

BarcelonaPre-Seed–Series A$2.2M – $4.3M

AFLPGGBC11 people

Debiopharm Innovation Fund

LausannePre-Seed–Late Stage$1M – $5M

MCTMTGVL13 people

Grazia Equity GmbH

StuttgartSeed–Late Stage$540K – $2.7M

ARJKASKU8 people

Amino Collective

BerlinPre-Seed–Series A$216K – $1.6M

MGNPFTCG8 people

Kinled Holding

Hong KongSeed–Series A

PA1 person

LBBW Venture Capital GmbH

StuttgartSeed–Late Stage$540K – $3.2M

AVFMCLMN9 people

Supermoon Capital

San FranciscoPre-Seed–Series A$150K – $2.5M

PCGJMMCZ6 people

Übermorgen Ventures

ZurichPre-Seed–Series A$330K – $1.1M

JHABALEW6 people

AMR Action Fund

BostonSeed–Series C

HSMHJGBB13 people

Auriga Partners

ParisSeed–Growth$540K – $5.4M

JCCLGRMC15 people

Pureos Bioventures

PfäffikonSeed–Series C

DEKBMMVG11 people

Simon Capital

DüsseldorfSeed–Series A$540K – $10.8M

FDJLNHNL5 people

Infinitas Capital

Pre-Seed–Late Stage

RLSLACAL16 people

Gimv

The HagueGrowth–Late Stage$21M – $430M

AJLTMMPV11 people

Novalis Biotech

GhentPre-Seed–Series A

JVWVKMJB9 people

Elysia Capital

Turin

MLSBFMFB7 people

PAI Partners

ParisGrowth–Late Stage$108M – $324M

AAAAEAEA8 people

TiVenture SA

LuganoPre-Seed–Series B

LLPODMRG5 people

Aescap Life Sciences

AmsterdamSeed–Growth

PKPDBJGH14 people

Ti-Ventures

LuganoPre-Seed–Series B

LLPODMRG5 people

Eurazeo

ParisSeries A–Late Stage

LGLMMTNW12 people

PM Equity Partner

LausanneSeries A–Growth$2M – $50M

AGACCODS9 people

Data sourced from public filings and firms' own websites — see our methodology.